Currently out of the existing stock ratings of Emily Bodnar, 247 are a BUY (85.17%), 43 are a HOLD (14.83%).

Emily Bodnar

Work Performance Price Targets & Ratings Chart

Analyst Emily Bodnar, carries an average stock price target met ratio of 29.64% that have a potential upside of 53.95% achieved within 86 days. Previously, Emily Bodnar worked at HC WAINWRIGHT.

Emily Bodnar’s has documented 496 price targets and ratings displayed on 30 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on OLMA, Olema Pharmaceuticals at 19-Oct-2025.

Wall Street Analyst Emily Bodnar

Analyst best performing recommendations are on BCTX (BRIACELL THERAPEUTICS CORP).
The best stock recommendation documented was for NVCR (NOVOCURE LTD) at 11/21/2024. The price target of $30 was fulfilled within 12 days with a profit of $12.91 (75.54%) receiving and performance score of 62.95.

Average potential price target upside

of $48534.92 (53.87%) on RNAZ (TRANSCODE THERAPEUTICS).
of $15.34 (58%) on NVCR (NOVOCURE LTD).
of $15.25 (31.07%) on BCTX (BRIACELL THERAPEUTICS CORP).

DICE Dice Molecules Holdings LLC FEMY Femasys NVCR Novocure Ltd OLMA Olema Pharmaceuticals VTYX Ventyx Biosciences SQZ Sqz Biotechnologies Co ACLX Arcellx BCTX Briacell Therapeutics Corp CNTX Context Therapeutics GRCL Gracell Biotechnologies INKT Mink Therapeutics IOBT IO Biotech NKTX Nkarta RNAZ Transcode Therapeutics AGEN Agenus SANA Sana Biotechnology JSPR Jasper Therapeutics ANAB AnaptysBio RCUS Arcus Biosciences GERN Geron NXTC NextCure ATOS Atossa Genetics CNTB Connect Biopharma Holdings Ltd ACRV Acrivon Therapeutics, Common Stock GNLX Genelux Common Stock PPBT Purple Biotech SLRN ACELYRIN, INC. Common Stock AGIO Agios Pharm RAPT RAPT Therapeutics VTVT vTv Therapeutics

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Emily Bodnar (HC WAINWRIGHT)